EUCRISA (crisaborole) Health Professional Information

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?


EUCRISA (crisaborole ointment, 2 %) is indicated for topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 3 months of age and older.

Pediatrics (3 months to <18 years): Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of EUCRISA have been established in pediatric patients age 3 months and older for topical treatment of mild to moderate atopic dermatitis.

Pediatrics (3 months of age): No data are available to Health Canada, therefore, Health Canada has not authorized an indication for pediatric patients below the age of 3 months.

Geriatrics (≥ 65 years of age):
Evidence from clinical studies of EUCRISA did not include sufficient numbers of patients 65 years of age and over to determine whether they respond differently from younger patients.